Bristol Myers wins, Apellis loses in busy week at Europe's drug regulator
Fierce Pharma
JANUARY 26, 2024
Shortly after Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended refusal of a marketing authorization | Shortly after Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended refusal of marketing authorization for Apellis’ geographic atrophy (GA) drug Syfovre (pegcetacoplan injection), the company said it will (..)
Let's personalize your content